- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04596397
Oral Misoprostol for Outpatient Induction of Labor
Oral Misoprostol for Outpatient Induction of Labor; a Pilot Randomized-controlled Trial
An increasing proportion of pregnant women have their labors induced due to changing guidelines. In correlation with this increase, the population of the induced women has changed toward more women with a low-risk pregnancy. Traditionally, induction of labor has taken place in an inpatient setting where the women have spent extra days in hospital before delivery.
Oral prostaglandins, such as misoprostol, is one of the most commonly used induction agent and is easy for the pregnant women to administrate. The pharmacological effect is ripening the cervix and compared to the mechanical cervical ripening, with a balloon catheter, the demands on busy maternity services seems reduced. Before contractions start, the risk of adverse effects on mother or fetus is considered low, but the evidence on use of misoprostol in an outpatient setting is sparse.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The implementation of induction of labor in outpatient settings is increasing despite insufficient evidence regarding safety and effectiveness. The use of a balloon catheter in an outpatient setting is not associated with adverse outcomes in a low-risk population. There is also evidence that outpatient vs inpatient induction of labor with balloon catheter is equally effective. Examination of vaginal dinoprostone (prostaglandin E2) is found to be efficacious in outpatient settings. However, strong evidence concludes that the oral route of administration of prostaglandin is preferable when inducing labor. The World Health Organization recommend 25ug misoprostol (prostaglandin E1) orally every 2 hour until contractions start for induction of labor.
The women randomized to an inpatient setting will receive the hospital standard follow-up; oral misoprostol 25ug every two hours and a cardiotocography for fetal monitoring every 4-6 hour until start of contractions for two days.
The women randomized to an outpatient setting will receive one oral misoprostol 25ug at the maternity unit. After two hours, provided a normal cardiotocography and no contractions, they can go home. They will continue to take 25ug misoprostol every two hours until start of contractions or increasing pain. Maximum time spent at home will be 48 hours.
A dedicated midwife on call will always be available for questions. The women will receive oral and written information to return to the maternity unit if the water breaks, if they experience increasing pain or bleeding, if they feel insecure or anxious, if there are reduced or no fetal movements, and/or when the contraction starts. When the woman returns, she will stay admitted until delivery.
All women will be given standard of care and fetal surveillance when admitted to the hospital, when the contractions start or if the contractions are still absent after 48 hours. We will also ask eligible women who refrain to participate about their reasons for non-participation.
PRIMARY RESEARCH QUESTION We aim to explore that induction of labor using oral misoprostol appears feasible in an outpatient setting and may positively influence the length of the hospital stay and maternal satisfaction.
PRIMARY RESEARCH PLAN This is a pilot study to explore the feasibility of a possible multicenter randomized controlled trail.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kristiansand, Norway, 4604
- Sorlandet Hospital Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Understand and read Norwegian
- No cognitive barriers. The woman must be able to give informed consent
- ≥ 37 gestational week, vertex presentation, single pregnancy
- Normal ultrasound including fetal movements, amniotic fluid, estimated fetal weight +/- 15% (≤ 10 percentile and ≥ 90) and normal doppler peak systolic index in the umbilical cord artery and the cerebri media artery
- Normal cardiotocography
- Body Mass Index 18-35
- No signs of infection or health problems
- Distance to hospital 45-60 minutes
Exclusion Criteria:
- Premature rupture of membranes
- Previous cesarean section or operation on uterus
- Fetal anomaly or chromosome/genetic disorder
- Pregnancy complications such as preeclampsia and diabetes (insulin dependent) or other conditions were changes in fetal heart rate during labor is suspected
- Not eligible for misoprostol as induction agent due a favorable cervix (Bishop score) and/or previous obstetric history
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Induction of labour with oral misoprostol, inpatient setting
These women receive all treatment in the maternity unit.
|
These women stay at the hospital.
|
Experimental: Induction of labour with oral misoprostol, outpatient setting
These women will be observed 2 hours after they receive one dose of oral misoprostol before the can leave the maternity unit.
|
These women can leave the hospital.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The feasibility of a randomised controlled trial of outpatient labor induction
Time Frame: 6 months
|
The number of eligible women who is willing to enrol in participating
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reported labor experience among the women participating
Time Frame: From included in the study until postpartum discharge (1-2 weeks)
|
The women will fill out a survey before and after birth (including childbirth expectations, experience and satisfaction)
|
From included in the study until postpartum discharge (1-2 weeks)
|
Maternal length of hospital stay
Time Frame: From included in the study until postpartum discharge (1-2 weeks)
|
Length of hospital stay form start of induction to postpartum discharge
|
From included in the study until postpartum discharge (1-2 weeks)
|
Use of analgesia
Time Frame: From start of the partogram until birth (hours)
|
Use of epidural and fentanyl analgesia during labor
|
From start of the partogram until birth (hours)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Janne Rossen, MD, PhD, Sorlandet Hospital Trust, Kristiansand, Norway
Publications and helpful links
General Publications
- Diederen M, Gommers J, Wilkinson C, Turnbull D, Mol B. Safety of the balloon catheter for cervical ripening in outpatient care: complications during the period from insertion to expulsion of a balloon catheter in the process of labour induction: a systematic review. BJOG. 2018 Aug;125(9):1086-1095. doi: 10.1111/1471-0528.15047. Epub 2018 Jan 10.
- Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, Alfirevic Z. Pharmacological and mechanical interventions for labour induction in outpatient settings. Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD007701. doi: 10.1002/14651858.CD007701.pub3.
- Wilkinson C, Bryce R, Adelson P, Turnbull D. A randomised controlled trial of outpatient compared with inpatient cervical ripening with prostaglandin E(2) (OPRA study). BJOG. 2015 Jan;122(1):94-104. doi: 10.1111/1471-0528.12846. Epub 2014 May 14.
- Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2014 Jun 13;2014(6):CD001338. doi: 10.1002/14651858.CD001338.pub3.
- WHO Recommendations for Induction of Labour. Geneva: World Health Organization; 2011. Available from http://www.ncbi.nlm.nih.gov/books/NBK131963/
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2020/104044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Labor Induction
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Northwestern UniversityCompletedLabor InductionUnited States
-
Mednax Center for Research, Education, Quality...Completed
-
Kanuni Sultan Suleyman Training and Research HospitalUnknown
-
University of ArizonaUnknownLabor InductionUnited States
-
Far Eastern Memorial HospitalCompleted
-
China Medical University HospitalCompleted
-
Icahn School of Medicine at Mount SinaiWithdrawn
-
Hadassah Medical OrganizationUnknown
-
Rambam Health Care CampusNot yet recruitingInduction of Labor
Clinical Trials on Inpatient setting
-
Yolanda Schlumpf, PhDUniversity of Zurich; Clienia Littenheid AGCompletedComplex Posttraumatic Stress Disorder (cPTSD) | Dissociative Disorder Not Otherwise Specified (DDNOS) | Dissociative Identity Disorder (DID)Switzerland
-
Sorlandet Hospital HFOstfold Hospital Trust; Haukeland University Hospital; St. Olavs Hospital; Nordlandssykehuset...Completed
-
University of Alabama at BirminghamUniversity of Maryland; University Teaching HospitalRecruitingHIV/AIDS | Tuberculosis | Cryptococcosis | Hospitalization | HIV Testing | Transitions of CareZambia
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
MedtronicNeuroWithdrawnFailed Back Surgery Syndrome | Arachnoiditis | Degenerative Disk Disease | Epidural Fibrosis | Radiculopathies
-
The University of Texas Health Science Center,...CompletedChronic IllnessesUnited States
-
Eunhee ChunEnrolling by invitationVentilators, MechanicalKorea, Republic of
-
Osaka UniversityUnknownCritical IllnessJapan
-
University Hospital, Clermont-FerrandRecruitingICU Patients | ARDS | Healthy Lung | Positive End-Expiratory Pressure | Alveolar Recruitment ManeuverFrance
-
Makerere UniversityUniversity of California, San FranciscoCompleted